ITGR at a glance
Integer Holdings Corp (ITGR, SEC CIK 1114483) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on October 2, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Integer Holdings Corp (ITGR) reported revenue of $1.9 billion (up 8.0% from FY2024) and net income of $102.8 million. Diluted EPS was $2.89.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Integer Holdings Corp (ITGR) shares worth $1.9 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Thor Kirk K on September 15, 2026 of 11,767 shares at $126.23 per share.
- In the last 90 days, ITGR insiders reported 0 open-market purchases ($0) and 3 open-market sales ($5.2M) on Form 4, a net sale of $5.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.9B
- +8.0% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$5.2M
- 13F holders
- 32 funds
- $1.9B · +0 vs prior quarter
- Latest 8-K
- Sep 30, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Pure-play medtech CDMO focused on Cardio & Vascular, Neuromodulation, and Cardiac Rhythm Management markets
- Acquisitions in 2025: Biocoat, VSi Parylene, and Precision Coatings added surface coating technologies and complementary capabilities
- Strategic emphasis on tuck-in acquisitions to expand capabilities, enhance scale, and deepen customer penetration in high-growth markets
- Firm backlog orders $675 million at December 31, 2025, majority expected to ship within one year
- Ongoing exit plan from Portable Medical market initiated in 2021, with final sales and exit expected in 2026
Risk Factors
- Regulatory risk: Compliance with EU Corporate Sustainability Reporting Directive and California climate rules may increase costs and impact profitability
- Geopolitical risk: Supply chain exposed to wars in Ukraine and Middle East, U.S.-China tensions, tariffs on steel and copper impacting import costs
- Operational risk: Top 3 customers accounted for 49% revenues in 2025; loss or reduced demand from any would materially harm results
- Competitive risk: Intense competition from medical device companies with greater resources and risk of customer insourcing or dual sourcing
- Financial risk: Dependence on senior management and key technical personnel; loss may harm operations and require costly replacement efforts
Management Discussion & Analysis
- Revenue $1.854B, up 8.0% YoY ($137M increase); Cardio & Vascular strongest segment $1.107B (+16.6%), Other Markets weakest $77.8M (-26.9%)
- Gross margin 27.0% vs 26.7% YoY, gross profit up 9.0% ($41.4M); operating expenses up $28.3M; net income down to $102.8M from $121.1M
- Operating cash flow $196.1M, capex $91.0M, share repurchase $50.0M; acquisitions funded by $178.9M borrowings; net debt $1.185B end of year
- Issued $1B 2030 Convertible Notes; paid down prior debt; repurchased 698K shares for $50M; increased working capital by $94.1M
- 2026 capex guidance $95M-$105M; management expects cash flows and credit facilities sufficient for operations and debt service; risk from foreign currency and restructuring costs
AI summary of the ITGR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jul 3, 2026
Management Discussion & Analysis
- Q2 revenue and YoY change not provided in supplied MD&A
- Profitability and margin percentages not provided in supplied MD&A
- Product-line performance comparisons not provided in supplied MD&A
- Merger agreement: $127-per-share cash consideration, $154M company termination fee
- 2026 sales outlook: lower revenue from three products due to lower-than-anticipated market adoption; supply-chain and tariff risks
Risk Factors
- Merger risk newly added after August 2, 2026 agreement, with completion subject to shareholder, antitrust, regulatory, and other closing conditions
- Transaction termination risk, including $154 million fee for specified Company breaches or superior proposal acceptance
- Regulatory and legal risk from Hart-Scott-Rodino and foreign-investment reviews, governmental orders, or merger litigation delaying or enjoining completion
- Operational risk from merger-related restrictions limiting contracts, acquisitions, indebtedness, and capital expenditures
- Financial risk from unrecouped merger expenses and potential share-price decline if completion fails
AI summary of the ITGR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Early HSR termination removes a major antitrust condition for KKR’s acquisition of Integer
- $127-per-share cash offer implies approximately $5.7 billion enterprise value
Item 8.01: Other Events
- Early HSR termination removes one U.S. antitrust condition for KKR-affiliated funds’ acquisition of Integer
- Merger remains subject to stockholder approval and other antitrust and foreign-investment approvals
Item 1.01: Entry into a Material Definitive Agreement
- KKR affiliates agreed to acquire Integer for $127 cash per share, taking the company private subject to customary conditions
- Shareholder approval, antitrust clearances and no material adverse effect required; transaction has no financing condition
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Bylaws effective August 2, 2026, adding exclusive-forum provisions for specified shareholder and corporate litigation
- Delaware Court of Chancery designated for covered corporate claims, or Delaware federal court if jurisdiction is lacking
AI summaries of ITGR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ITGR
Don't miss the next ITGR filing
- Alerts as it files. A push when ITGR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ITGR, by share count.
- Ask anything. An AI agent that reads every ITGR filing and answers with sources.
ITGR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Thor Kirk K | Sell | Sep 15, 2026 | 11,767 | $126.23 |
| Thor Kirk K | Sell | Sep 14, 2026 | 19,773 | $126.25 |
| Senn Andrew | Sell | Sep 8, 2026 | 9,408 | $126.30 |
| Metcalf Milo Stephen II | A | Jul 6, 2026 | 892 | - |
| Metcalf Milo Stephen II | A | Jul 6, 2026 | 4,532 | - |
| Thor Kirk K | F | Jun 30, 2026 | 2,409 | $93.45 |
| Thor Kirk K | M | Jun 30, 2026 | 6,120 | - |
| Thor Kirk K | M | Jun 30, 2026 | 6,120 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.7B | $1.9B |
| Gross Profit | - | $459.0M | $500.4M |
| Operating Income | - | $208.2M | $221.3M |
| Net Income | - | $119.9M | $102.8M |
| Gross Margin | - | 26.7% | 27.0% |
| Op. Margin | - | 12.1% | 11.9% |
| Net Margin | - | 7.0% | 5.5% |
| Balance Sheet | |||
| Total Assets | $2.9B | $3.1B | $3.4B |
| Equity | $1.5B | $1.6B | $1.7B |
| ROE | - | 7.4% | 5.9% |
| Per Share | |||
| EPS | - | $3.36 | $2.89 |
| Cash Flow | |||
| Operating CF | - | $205.2M | $196.1M |
| CapEx | - | $105.4M | $91.0M |
Source: XBRL data in Integer Holdings Corp (ITGR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ITGR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $1.93B |
| Q1 2026 | 32 | $1.75B |
| Q4 2025 | 31 | $1.46B |
| Q3 2025 | 34 | $2.25B |
| Q2 2025 | 32 | $2.77B |
| Q1 2025 | 30 | $1.87B |
| Q4 2024 | 28 | $1.87B |
| Q3 2024 | 25 | $1.14B |
- Invesco Ltd+277.9K (+14%)
- Citadel Advisors LLC+272.7K (+39%)
- Goldman Sachs Group+231.2K (+67%)
- JPMorgan Chase & Co+202.6K (+120%)
- Dimensional Fund Advisors+143.4K (+10%)
- Morgan Stanley−193.5K (-13%)
- D.E. Shaw & Co−115.1K (-78%)
- Millennium Management−100.9K (-22%)
- Franklin Resources−100.3K (-30%)
- Bank of America Corp−96.7K (-17%)
- Blackstone Group+2.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 244 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ITGR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 2, 2026 | - | - | - |
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 4, 2026 | Jul 3, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 8-K | May 22, 2026 | - | Analysis | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- LIVN · LivaNova PLCElectromedical & Electrotherapeutic Apparatus
ITGR SEC filings: frequently asked questions
Are ITGR insiders buying or selling?
In the last 90 days, Integer Holdings Corp (ITGR) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $5.2 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ITGR stock?
As of June 30, 2026, the largest Integer Holdings Corp (ITGR) holders among the 13F filers tracked by SignalX were BlackRock ($500.3 million), Invesco Ltd ($210.0 million), Vanguard Portfolio Management LLC ($190.7 million), Dimensional Fund Advisors ($152.1 million), Vanguard Capital Management LLC ($143.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ITGR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Integer Holdings Corp (ITGR) reported revenue of $1.9 billion (up 8.0% from FY2024) and net income of $102.8 million. Diluted EPS was $2.89. The figures come from the XBRL data in the 10-K.
What are the main risks in ITGR's latest 10-K?
In the 10-K filed February 23, 2026, Integer Holdings Corp (ITGR) flagged: Regulatory risk: Compliance with EU Corporate Sustainability Reporting Directive and California climate rules may increase costs and impact profitability. Geopolitical risk: Supply chain exposed to wars in Ukraine and Middle East, U.S.-China tensions, tariffs on steel and copper impacting import costs. (AI summary of the Risk Factors section.)
What did ITGR report in its latest 8-K?
Integer Holdings Corp (ITGR) filed an 8-K on September 30, 2026 reporting Item 8.01 (Other Events). Early HSR termination removes a major antitrust condition for KKR’s acquisition of Integer.
What are the latest ITGR SEC filings?
Integer Holdings Corp (ITGR) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on October 2, 2026 and a Form 4 insider filing on September 16, 2026.
What is ITGR's SEC CIK number?
Integer Holdings Corp (ITGR)'s SEC Central Index Key (CIK) is 1114483. EDGAR lists every ITGR filing under that number.
Ask anything about ITGR
The research agent reads ITGR's filings, financials, insider trades and 13F holders, then answers with sources.